M.J. Lechuga

656 total citations
18 papers, 351 citations indexed

About

M.J. Lechuga is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M.J. Lechuga has authored 18 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in M.J. Lechuga's work include Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). M.J. Lechuga is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). M.J. Lechuga collaborates with scholars based in Italy, Spain and United States. M.J. Lechuga's co-authors include Xun Lin, Beata Korytowsky, Robin Wiltshire, Ewa Matczak, Ana M. Molina, Robert J. Motzer, Jesús Devesa, Noemi Lois, Luis Lima and Vı́ctor M. Arce and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of the New York Academy of Sciences.

In The Last Decade

M.J. Lechuga

18 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.J. Lechuga Italy 10 150 130 98 77 64 18 351
Toshiya Soma Japan 10 163 1.1× 52 0.4× 94 1.0× 44 0.6× 86 1.3× 12 423
Brigitte Van Eyll Brazil 9 124 0.8× 90 0.7× 90 0.9× 42 0.5× 209 3.3× 13 354
Andrew Do United States 11 143 1.0× 233 1.8× 60 0.6× 77 1.0× 179 2.8× 21 443
Caroline Ward United Kingdom 11 76 0.5× 57 0.4× 67 0.7× 67 0.9× 99 1.5× 20 404
Sophie Corroyer France 13 191 1.3× 169 1.3× 77 0.8× 103 1.3× 89 1.4× 13 433
Varun Kumar Germany 9 121 0.8× 47 0.4× 60 0.6× 22 0.3× 36 0.6× 15 315
N. Okada Japan 8 112 0.7× 71 0.5× 80 0.8× 11 0.1× 24 0.4× 23 351
Candace Wise United States 9 62 0.4× 39 0.3× 19 0.2× 51 0.7× 92 1.4× 9 315
Michael Schonfeld United States 13 216 1.4× 82 0.6× 16 0.2× 89 1.2× 22 0.3× 21 423
Madeleine Themanns Austria 9 136 0.9× 22 0.2× 79 0.8× 44 0.6× 72 1.1× 15 323

Countries citing papers authored by M.J. Lechuga

Since Specialization
Citations

This map shows the geographic impact of M.J. Lechuga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.J. Lechuga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.J. Lechuga more than expected).

Fields of papers citing papers by M.J. Lechuga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.J. Lechuga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.J. Lechuga. The network helps show where M.J. Lechuga may publish in the future.

Co-authorship network of co-authors of M.J. Lechuga

This figure shows the co-authorship network connecting the top 25 collaborators of M.J. Lechuga. A scholar is included among the top collaborators of M.J. Lechuga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.J. Lechuga. M.J. Lechuga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Molina, Ana M., Xun Lin, Beata Korytowsky, et al.. (2013). Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. European Journal of Cancer. 50(2). 351–358. 111 indexed citations
2.
Oh, Do‐Youn, Reza Khosravan, Xun Lin, et al.. (2013). Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. Investigational New Drugs. 31(6). 1547–1558. 20 indexed citations
3.
Gómez-Martín, Carlos, Ramón Salazar, Clara Montagut, et al.. (2012). A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Investigational New Drugs. 31(2). 390–398. 15 indexed citations
4.
Carrato, Alfredo, Feng Gao, James A. Williams, et al.. (2011). Abstract 289: Associations between germline genotype and efficacy and safety outcomes in a phase III study of sunitinib (SU) and FOLFIRI in metastatic colorectal cancer (mCRC). Cancer Research. 71(8_Supplement). 289–289. 1 indexed citations
5.
Cheng, Ann‐Lii, Silvana Lanzalone, M.J. Lechuga, et al.. (2008). Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters. Journal of Clinical Oncology. 26(15_suppl). 4593–4593. 7 indexed citations
6.
Faivre, Sandrine, Éric Raymond, Jean‐Yves Douillard, et al.. (2007). Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 25(18_suppl). 3546–3546. 49 indexed citations
7.
Faivre, Sandrine, Éric Raymond, Jean-Yves Douillard, et al.. (2007). 3535 POSTER Phase II trial investigating the efficacy and safety of sunitinib in patients with unresectable hepatocellular carcinoma (HCC). European Journal of Cancer Supplements. 5(4). 270–270. 4 indexed citations
8.
Kang, W., Narikazu Boku, Heewon Chung, et al.. (2007). 3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer. European Journal of Cancer Supplements. 5(4). 272–272. 3 indexed citations
9.
Vázquez, Francisca, Alfredo Carrato, Naureen Starling, et al.. (2007). 3065 POSTER Safety and efficacy of sunitinib and FOLFIRI in combination in treatment-naive metastatic colorectal cancer (mCRC): a phase I study. European Journal of Cancer Supplements. 5(4). 255–256. 2 indexed citations
10.
Reck, Martin, N. Frickhofen, U. Gatzemeier, et al.. (2007). A phase I dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 18057–18057. 14 indexed citations
11.
Jonge, Maja J.A. de, Jaap Verweij, Ate van der Gaast, et al.. (2002). Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. European Journal of Cancer. 38(18). 2407–2415. 4 indexed citations
12.
Martini, L., F. Celotti, M.J. Lechuga, et al.. (1990). Androgen Metabolism in Different Target Tissues. Annals of the New York Academy of Sciences. 595(1). 184–198. 12 indexed citations
13.
Devesa, Jesús, Luis Lima, Noemi Lois, et al.. (1989). REASONS FOR THE VARIABILITY IN GROWTH HORMONE (GH) RESPONSES TO GHRH CHALLENGE: THE ENDOGENOUS HYPOTHALAMIC‐SOMATOTROPH RHYTHM (HSR). Clinical Endocrinology. 30(4). 367–377. 67 indexed citations
14.
Lima, Luis, Vı́ctor M. Arce, Noemi Lois, et al.. (1989). Growth hormone (GH) responsiveness to GHRH in normal adults is not affected by short-term gonadal blockade. European Journal of Endocrinology. 120(1). 31–36. 19 indexed citations
15.
Zoppi, S., et al.. (1988). Antihormonal activities of 5α-reductase and aromatase inhibitors. Journal of Steroid Biochemistry. 31(4). 677–683. 11 indexed citations
16.
Facchinetti, Fabio, et al.. (1988). Dopamine acts on acetylation of proopiomelanocortin-derived products in dog pituitary. European Journal of Endocrinology. 117(1). 33–38. 10 indexed citations
17.
Zoppi, S., et al.. (1988). Effect of enzyme inhibitors and of LHRH analogs on androgen metabolism in human prostate. 293–299. 1 indexed citations
18.
Lechuga, M.J., et al.. (1978). Energy for development of the Philippines. Energy. 3(1). 15–21. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiya Soma Breakdown of academic impact, for papers by Brigitte Van Eyll Breakdown of academic impact, for papers by Andrew Do Breakdown of academic impact, for papers by Caroline Ward Breakdown of academic impact, for papers by Sophie Corroyer Breakdown of academic impact, for papers by Varun Kumar Breakdown of academic impact, for papers by N. Okada Breakdown of academic impact, for papers by Candace Wise Breakdown of academic impact, for papers by Michael Schonfeld Breakdown of academic impact, for papers by Madeleine Themanns
Rankless by CCL
2026